Loading clinical trials...

Ancillary Effects of Dexmedetomidine Sedation After Cardiac Surgery | Clinical Trials | Clareo Health

COMPLETEDPHASE4

Ancillary Effects of Dexmedetomidine Sedation After Cardiac Surgery

NCT02004613•The Cleveland Clinic

View on ClinicalTrials.gov

Summary

Detailed Description

The investigator goal is to evaluate the effects of intraoperative and postoperative dexmedetomidine sedation (versus placebo after cardiac surgery.

Eligibility

Age

18 - 85 years

Sex

ALL

Healthy Volunteers

Yes

Inclusion Criteria

•1. 18-85 years old;
•2. Scheduled for cardiac surgery with bypass (CABG, valve, or combined);
•3. Able to provide a written informed consent;
•4. Hemodynamically stable (heart rate\>= 55).

Exclusion Criteria

•1. Sick sinus syndrome or Wolff-Parkinson-White syndrome
•2. Atrio-ventricular block
•3. Hypersensitivity or known allergy to dexmedetomidine
•4. Hepatic disease, e.g. twice the normal level of liver enzymes
•5. Atrial fibrillation within 1 preoperative month;
•6. Permanent pacemaker;
•7. Use of amiodarone or dexmedetomidine within the last 30 days;
•8. Patients with an ejection fraction under 30% or who had severe heart failure
•9. Myocardial infarction in the previ¬ous 7 days;
•10. Body mass index =\< 40 (BMI= mass (kg) / height (m)2);
+1 more criteria

Locations (1)

Cleveland Clinic Main

Cleveland, Ohio, United States

Key Dates

Start Date

June 1, 2013

Primary Completion Date

December 1, 2018

Completion Date

December 18, 2020

Last Updated

April 6, 2021

Enrollment

798

ACTUAL participants

Conditions

Heart Disease

Interventions

Dexmedetomidine

DRUG

Placebo

DRUG

Characterization and Support of Neurodevelopmental Disorders Associated With Congenital Cardiac malfoRmations - Neonatal

NCT06690151

Heart Disease CongenitalNeurodevelopmental Disorder

View study

RECRUITINGPHASE1

Autologous Induced Pluripotent Stem Cells of Cardiac Lineage for Congenital Heart Disease

NCT05647213

Univentricular HeartCongenital Heart Disease+2 more

View study

Data Source & Attribution

This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.

ClinicalTrials.gov last update: April 6, 2021Data synced to Clareo: March 29, 2026

Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.

Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.

View ClinicalTrials.gov Terms and Conditions

Ancillary Effects of Dexmedetomidine Sedation After Cardiac Surgery

Inclusion Criteria

Exclusion Criteria

Characterization and Support of Neurodevelopmental Disorders Associated With Congenital Cardiac malfoRmations - Neonatal

Autologous Induced Pluripotent Stem Cells of Cardiac Lineage for Congenital Heart Disease

Sildinafil in Pulmonary Hypertension-Rheumatic Chronic Valvular Disease(RCT)

Prospective Evaluation of AI-ECG for SHD Detection

Lumason® Infusion vs. Bolus Administrations

PPG to Predict Ejection Fraction and Other Echographic Data in the General Population